- Home
- NGNE vs ARAI Comparison
NGNE vs ARAI Comparison
Compare NGNE & ARAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- ARAI
- Stock Information
- Founded
- NGNE 2003
- ARAI 2020
- Country
- NGNE United States
- ARAI United States
- Employees
- NGNE N/A
- ARAI N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- ARAI Diversified Commercial Services
- Sector
- NGNE Health Care
- ARAI Finance
- Exchange
- NGNE Nasdaq
- ARAI Nasdaq
- Market Cap
- NGNE 325.3M
- ARAI 213.7M
- IPO Year
- NGNE N/A
- ARAI N/A
- Fundamental
- Price
- NGNE $18.48
- ARAI $4.80
- Analyst Decision
- NGNE Strong Buy
- ARAI
- Analyst Count
- NGNE 7
- ARAI 0
- Target Price
- NGNE $41.86
- ARAI N/A
- AVG Volume (30 Days)
- NGNE 110.1K
- ARAI 180.4K
- Earning Date
- NGNE 08-11-2025
- ARAI 08-14-2025
- Dividend Yield
- NGNE N/A
- ARAI N/A
- EPS Growth
- NGNE N/A
- ARAI N/A
- EPS
- NGNE N/A
- ARAI N/A
- Revenue
- NGNE N/A
- ARAI $90,725.00
- Revenue This Year
- NGNE N/A
- ARAI N/A
- Revenue Next Year
- NGNE N/A
- ARAI N/A
- P/E Ratio
- NGNE N/A
- ARAI N/A
- Revenue Growth
- NGNE N/A
- ARAI N/A
- 52 Week Low
- NGNE $6.88
- ARAI $4.61
- 52 Week High
- NGNE $74.49
- ARAI $40.00
- Technical
- Relative Strength Index (RSI)
- NGNE 35.93
- ARAI N/A
- Support Level
- NGNE $19.59
- ARAI N/A
- Resistance Level
- NGNE $20.46
- ARAI N/A
- Average True Range (ATR)
- NGNE 1.23
- ARAI 0.00
- MACD
- NGNE -0.20
- ARAI 0.00
- Stochastic Oscillator
- NGNE 13.37
- ARAI 0.00
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About ARAI Arrive AI Inc. Common Stock
Arrive AI Inc is a technology company. Its patented Autonomous Last Mile (ALM) platform enables secure, efficient delivery to and from a smart, AI-powered mailbox-whether by drone, ground robot, or human courier. The platform provides real-time tracking, smart logistics alerts, and advanced chain-of-custody controls to support shippers, delivery services, and autonomous networks. By combining artificial intelligence with autonomous technology, Arrive AI makes the exchange of goods between people, robots, and drones frictionless and convenient. Its system integrates with smart home devices such as doorbells, lighting, and security systems to streamline the entire last-mile delivery experience.